A study to detect numerical aberrations of cyclin D1 gene using Fluorescence in situ hybridization technique among patients of oral squamous cell carcinoma-IJASHNB-Print ISSN No:-2581-5210 Online ISSN No:-2581-5229Article DOI No:-10.18231/j.ijashnb.2020.025,IP Indian Journal of Anatomy and Surgery of Head, Neck and Bra
Schizophrenia‐spectrum disorders are characterized by psychotic symptoms, including hallucinations, delusions, and disorganized thinking. Schneider’s first‐rank symptoms (FRS)—including thought broadcasting and experiences of external control—are clinically salient but not ergonomic and require careful differential diagnosis. The emergence of new‐onset psychosis in midlife, particularly in individuals without prior psychotic history, warrants a broad biopsychosocial evaluation. We present the case of a 47‐year‐old male with chronic major depressive disorder and complex developmental trauma who developed abrupt FRS‐like phenomena (prominently thought broadcasting) and auditory hallucinations following a period marked by (1) severe pneumonia with lung abscess, (2) escalating anxiety and depressive distress, (3) exposure to substances including reported synthetic cannabinoids (“Spice”) with a urine toxicology positive for amphetamines, and (4) neuromodulation via 20 sessions of transcranial magnetic stimulation (TMS). Concurrently, the patient experienced a severe psychosocial/legal stressor (investigation related to child sexual exploitation material), associated with profound shame and fear. Rather than attributing symptoms to a single trigger, this case highlights a convergence model—medical inflammation, substance toxicity, trauma‐related vulnerability, and acute legal stress—potentially disrupting cerebral homeostasis and precipitating psychosis and suicidality. Treatment included discontinuation of TMS, pharmacologic stabilization, and intensive psychotherapy, with partial remission of psychotic symptoms. There is a need for structured monitoring for emergent psychosis and multidimensional suicide risk in high‐risk patients receiving neuromodulation.
Rapid methadone metabolism in patients with opioid use disorder could complicate methadone treatment. Toxicology screenings to monitor methadone levels may show negative for methadone, even with regular adherence to a regimen. A patient receiving treatment for opioid use disorder tested negative for methadone in 11 out of 22 toxicology screenings (50.0%). We hypothesized that the patient was a rapid methadone metabolizer. After tapering doses to a maintenance level and using supervised urine collection, the patient was negative for methadone in seven out of seven tests (100.0%), but positive for cocaine in five out of seven tests (71.4%) near the end of the maintenance period. Chronic cocaine use and genetic factors, particularly CYP2B6 polymorphisms, have been found to cause rapid methadone metabolism. Clinicians should be vigilant for unusual metabolic reactions and modify dose and monitoring schedules accordingly. More investigation into the physiological and genetic aspects of methadone metabolism is needed.
Rapid methadone metabolism in patients with opioid use disorder could complicate methadone treatment. Toxicology screenings to monitor methadone levels may show negative for methadone, despite adherence regular regimen. A patient receiving treatment for opioid use disorder tested negative for methadone in 11 out of 22 toxicology screenings (50.0%). We hypothesized that the patient was a rapid methadone metabolizer. After tapering doses to a maintenance level and using supervised urine collection, the patient was negative for methadone in 7 out of 7 tests (100.0%) but positive for cocaine in 5 out of 7 tests (71.4%). Chronic cocaine use and genetic factors, particularly CYP2B6 polymorphisms, have been found to cause rapid methadone metabolism. Clinicians should be vigilant for unusual metabolic reactions and modify dose and monitoring schedules accordingly. More investigation into the physiological and genetic aspects of methadone metabolism is needed.